vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
SIMMONS FIRST NATIONAL CORP is the larger business by last-quarter revenue ($197.3M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). On growth, SIMMONS FIRST NATIONAL CORP posted the faster year-over-year revenue change (19.6% vs 5.0%). Over the past eight quarters, SIMMONS FIRST NATIONAL CORP's revenue compounded faster (0.6% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
PCRX vs SFNC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $197.3M |
| Net Profit | $2.9M | — |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | — |
| Revenue YoY | 5.0% | 19.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $197.3M | ||
| Q3 25 | $179.5M | $186.7M | ||
| Q2 25 | $181.1M | $214.2M | ||
| Q1 25 | $168.9M | $209.6M | ||
| Q4 24 | $187.3M | $208.5M | ||
| Q3 24 | $168.6M | $174.8M | ||
| Q2 24 | $178.0M | $197.2M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-562.8M | ||
| Q2 25 | $-4.8M | $54.8M | ||
| Q1 25 | $4.8M | $32.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $24.7M | ||
| Q2 24 | $18.9M | $40.8M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 4.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | -82.8% | — | ||
| Q2 24 | 15.9% | — |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -301.5% | ||
| Q2 25 | -2.7% | 25.6% | ||
| Q1 25 | 2.8% | 15.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 14.1% | ||
| Q2 24 | 10.6% | 20.7% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.36 | ||
| Q3 25 | $0.12 | $-4.00 | ||
| Q2 25 | $-0.11 | $0.43 | ||
| Q1 25 | $0.10 | $0.26 | ||
| Q4 24 | $0.38 | $0.38 | ||
| Q3 24 | $-3.11 | $0.20 | ||
| Q2 24 | $0.39 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | — |
| Total DebtLower is stronger | — | $620.0M |
| Stockholders' EquityBook value | $653.9M | $3.4B |
| Total Assets | $1.2B | $24.5B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $620.0M | ||
| Q3 25 | $376.7M | $667.8M | ||
| Q2 25 | $580.5M | $1.0B | ||
| Q1 25 | $583.4M | $1.3B | ||
| Q4 24 | $585.3M | $1.1B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.7B |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $3.4B | ||
| Q3 25 | $727.2M | $3.4B | ||
| Q2 25 | $757.8M | $3.5B | ||
| Q1 25 | $798.5M | $3.5B | ||
| Q4 24 | $778.3M | $3.5B | ||
| Q3 24 | $749.6M | $3.5B | ||
| Q2 24 | $879.3M | $3.5B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $24.5B | ||
| Q3 25 | $1.3B | $24.2B | ||
| Q2 25 | $1.5B | $26.7B | ||
| Q1 25 | $1.6B | $26.8B | ||
| Q4 24 | $1.6B | $26.9B | ||
| Q3 24 | $1.5B | $27.3B | ||
| Q2 24 | $1.6B | $27.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.18× | ||
| Q3 25 | 0.52× | 0.20× | ||
| Q2 25 | 0.77× | 0.28× | ||
| Q1 25 | 0.73× | 0.35× | ||
| Q4 24 | 0.75× | 0.32× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.50× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $449.5M |
| Free Cash FlowOCF − Capex | — | $411.4M |
| FCF MarginFCF / Revenue | — | 208.5% |
| Capex IntensityCapex / Revenue | — | 19.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $449.5M | ||
| Q3 25 | $60.8M | $223.4M | ||
| Q2 25 | $12.0M | $77.6M | ||
| Q1 25 | $35.5M | $32.8M | ||
| Q4 24 | $33.1M | $425.9M | ||
| Q3 24 | $53.9M | $199.4M | ||
| Q2 24 | $53.2M | $86.1M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $411.4M | ||
| Q3 25 | $57.0M | $216.7M | ||
| Q2 25 | $9.3M | $66.3M | ||
| Q1 25 | $26.9M | $22.6M | ||
| Q4 24 | $31.0M | $380.4M | ||
| Q3 24 | $49.8M | $187.7M | ||
| Q2 24 | $51.6M | $72.7M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 208.5% | ||
| Q3 25 | 31.7% | 116.1% | ||
| Q2 25 | 5.1% | 31.0% | ||
| Q1 25 | 15.9% | 10.8% | ||
| Q4 24 | 16.6% | 182.5% | ||
| Q3 24 | 29.6% | 107.4% | ||
| Q2 24 | 29.0% | 36.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 19.3% | ||
| Q3 25 | 2.2% | 3.6% | ||
| Q2 25 | 1.5% | 5.3% | ||
| Q1 25 | 5.1% | 4.8% | ||
| Q4 24 | 1.1% | 21.8% | ||
| Q3 24 | 2.4% | 6.7% | ||
| Q2 24 | 0.9% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | 7.37× | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.06× | ||
| Q2 24 | 2.82× | 2.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SFNC
Segment breakdown not available.
